Treatment of chronic fatigue syndrome (systemic exertion intolerance disease)
- Stephen J Gluckman, MD
Stephen J Gluckman, MD
- Professor of Medicine
- University of Pennsylvania School of Medicine
Chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID), is a complicated and sometimes controversial disease characterized by unexplained, persistent, and relapsing fatigue. Diagnosis can be difficult due to the lack of a diagnostic test with adequate sensitivity and specificity. The long-term prognosis is unpredictable, and only about 15 percent of patients make a full recovery.
The treatment of CFS/SEID will be reviewed here. The clinical features and diagnosis of this disorder and the approach to the patient with fatigue are discussed separately. (See "Clinical features and diagnosis of chronic fatigue syndrome (systemic exertion intolerance disease)" and "Approach to the adult patient with fatigue".)
Many therapies have been tried in patients with chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID), but none is curative. Management is supportive and focuses on treating common comorbid conditions, which include sleep disorders, pain, depression and anxiety, memory and concentration difficulties, and dizziness and lightheadedness. Counseling therapies (eg, cognitive behavioral therapy [CBT]) and graded exercise therapy (GET) may be beneficial in some patients [1-3].
Many controversies remain about the optimal management of CFS/SEID. Clinicians and patients should be cautious about the use of unproven interventions that are potentially dangerous and often expensive.
Supportive approach — The best approach for the clinician is to establish a rapport with the patient to be able to provide support and reassurance.
Subscribers log in hereLiterature review current through: Sep 2017. | This topic last updated: Oct 09, 2017.References
- Whiting P, Bagnall AM, Sowden AJ, et al. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001; 286:1360.
- Smith MEB, Nelson HD, Haney E, Pappas M, Daeges M, Wasson N, McDonagh M. Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Evidence Report/Technology Assessment No. 219. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 15-E001-EF. Rockville, MD: Agency for Healthcare Research and Quality; December 2014. www.effectivehealthcare.ahrq.gov/reports/final/cfm.
- Smith ME, Haney E, McDonagh M, et al. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:841.
- Cluff LE. Medical aspects of delayed convalescence. Rev Infect Dis 1991; 13 Suppl 1:S138.
- Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness. Washington, DC: The National Academies Press, 2015.
- Sharpe M, Hawton K, Seagroatt V, Pasvol G. Follow up of patients presenting with fatigue to an infectious diseases clinic. BMJ 1992; 305:147.
- https://www.cdc.gov/me-cfs/treatment/index.html (Accessed on October 05, 2017).
- Sharpe M, Hawton K, Simkin S, et al. Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial. BMJ 1996; 312:22.
- Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry 1997; 154:408.
- Deale A, Husain K, Chalder T, Wessely S. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. Am J Psychiatry 2001; 158:2038.
- White PD, Goldsmith KA, Johnson AL, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011; 377:823.
- Nijhof SL, Bleijenberg G, Uiterwaal CS, et al. Effectiveness of internet-based cognitive behavioural treatment for adolescents with chronic fatigue syndrome (FITNET): a randomised controlled trial. Lancet 2012; 379:1412.
- Schröder A, Rehfeld E, Ornbøl E, et al. Cognitive-behavioural group treatment for a range of functional somatic syndromes: randomised trial. Br J Psychiatry 2012; 200:499.
- Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 2001; 357:841.
- Price JR, Mitchell E, Tidy E, Hunot V. Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database Syst Rev 2008; :CD001027.
- White PD, Chalder T. Chronic fatigue syndrome: treatment without a cause. Lancet 2012; 379:1372.
- O'Dowd H, Gladwell P, Rogers CA, et al. Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme. Health Technol Assess 2006; 10:iii.
- Jason LA, Torres-Harding S, Friedberg F, et al.. Non-pharmacologic Interventions for CFS: A Randomized Trial. Journal of Clinical Psychology in Medical Settings 2007; 14:275.
- Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev 2017; 4:CD003200.
- Fulcher KY, White PD. Strength and physiological response to exercise in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 2000; 69:302.
- Fulcher KY, White PD. Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. BMJ 1997; 314:1647.
- Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev 2016; 2:CD003200.
- Clark LV, Pesola F, Thomas JM, et al. Guided graded exercise self-help plus specialist medical care versus specialist medical care alone for chronic fatigue syndrome (GETSET): a pragmatic randomised controlled trial. Lancet 2017; 390:363.
- Sisto SA, LaManca J, Cordero DL, et al. Metabolic and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome. Am J Med 1996; 100:634.
- Geraghty K, Hann M, Kurtev S. Myalgic encephalomyelitis/chronic fatigue syndrome patients' reports of symptom changes following cognitive behavioural therapy, graded exercise therapy and pacing treatments: Analysis of a primary survey compared with secondary surveys. J Health Psychol 2017; :1359105317726152.
- Powell P, Bentall RP, Nye FJ, Edwards RH. Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome. BMJ 2001; 322:387.
- Jason L, Benton M, Torres-Harding S, Muldowney K. The impact of energy modulation on physical functioning and fatigue severity among patients with ME/CFS. Patient Educ Couns 2009; 77:237.
- Brown M, Khorana N, Jason LA. The role of changes in activity as a function of perceived available and expended energy in nonpharmacological treatment outcomes for ME/CFS. J Clin Psychol 2011; 67:253.
- Kewley AJ. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377:1832; author reply 1834.
- Stouten B, Goudsmit EM, Riley N. The PACE trial in chronic fatigue syndrome. Lancet 2011; 377:1832.
- https://www.nice.org.uk/guidance/conditions-and-diseases/chronic-fatigue-syndrome (Accessed on October 09, 2017).
- http://www.topalbertadoctors.org/cpgs/0242896 (Accessed on October 09, 2017).
- Straus SE. Pharmacotherapy of chronic fatigue syndrome: another gallant attempt. JAMA 2004; 292:1234.
- McDermott C, Richards SC, Thomas PW, et al. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. QJM 2006; 99:461.
- Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. N Engl J Med 1988; 319:1692.
- Vercoulen JH, Swanink CM, Zitman FG, et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347:858.
- Natelson BH, Cheu J, Pareja J, et al. Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology (Berl) 1996; 124:226.
- Reid S, Chalder T, Cleare A, et al. Chronic fatigue syndrome. BMJ 2000; 320:292.
- Roerink ME, Bredie SJH, Heijnen M, et al. Cytokine Inhibition in Patients With Chronic Fatigue Syndrome: A Randomized Trial. Ann Intern Med 2017; 166:557.
- Blacker CV, Greenwood DT, Wesnes KA, et al. Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. JAMA 2004; 292:1195.
- McKenzie R, O'Fallon A, Dale J, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998; 280:1061.
- Cleare AJ, Heap E, Malhi GS, et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999; 353:455.
- DuBois RE. Gamma globulin therapy for chronic mononucleosis syndrome. AIDS Res 1986; 2 Suppl 1:S191.
- Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990; 89:554.
- Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997; 103:38.
- Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med 2006; 119:167.e23.
- Randall DC, Cafferty FH, Shneerson JM, et al. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005; 19:647.
- Fluge Ø, Bruland O, Risa K, et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One 2011; 6:e26358.
- Lightfoot RW Jr, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Ann Intern Med 1993; 119:503.
- Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274:961.
- Rowe PC, Calkins H. Neurally mediated hypotension and chronic fatigue syndrome. Am J Med 1998; 105:15S.
- Peterson PK, Pheley A, Schroeppel J, et al. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998; 158:908.
- Rowe PC, Calkins H, DeBusk K, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA 2001; 285:52.
- Blockmans D, Persoons P, Van Houdenhove B, et al. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. Am J Med 2003; 114:736.
- Bombardier CH, Buchwald D. Outcome and prognosis of patients with chronic fatigue vs chronic fatigue syndrome. Arch Intern Med 1995; 155:2105.
- Roberts E, Wessely S, Chalder T, et al. Mortality of people with chronic fatigue syndrome: a retrospective cohort study in England and Wales from the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Clinical Record Interactive Search (CRIS) Register. Lancet 2016; 387:1638.
- Clark MR, Katon W, Russo J, et al. Chronic fatigue: risk factors for symptom persistence in a 2 1/2-year follow-up study. Am J Med 1995; 98:187.
- MANAGEMENT OVERVIEW
- Supportive approach
- Common symptoms/comorbidities
- Work modifications
- POTENTIALLY BENEFICIAL INTERVENTIONS
- Cognitive behavioral therapy
- Exercise therapy
- Limitations of studies
- USE OF MEDICATIONS AND DIET
- NEURALLY MEDIATED HYPOTENSION
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS